Seres Therapeutics vs Oramed Pharmaceuticals
MCRB and ORMP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MCRB and ORMP compare
Oramed Pharmaceuticals is the larger company, worth 12 times as much as Seres Therapeutics ($172M against $14.9M).
Oramed Pharmaceuticals pays a dividend yielding 6.1%; Seres Therapeutics does not pay one.
Oramed Pharmaceuticals scores higher on the StockData Score (12 against 7 for Seres Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MCRB | ORMP |
|---|---|---|
| Size and price | ||
| Market cap | $14.9M | $172M |
| Share price | $1.50 | $4.13 |
| Change, 1 year | −89.3% | 81.1% |
| Change, 5 years | −99.2% | −84.4% |
| Beta (5Y) | 1.02 | 1.44 |
| Employees | 66 | 13 |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 1.0× |
| P/S | 7.0× | – |
| P/B | 0.7× | – |
| PEG | – | 0.04 |
| FCF yield | −429% | −3.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 505% | – |
| Revenue growth, 5Y average | −52.7% | −5.8% (better) |
| Net income growth (TTM) | −970% | – |
| EPS growth (TTM) | −931% | – |
| EPS growth, 5Y average | – | 12.8% |
| Profitability | ||
| Operating margin | −3657% | – |
| Net margin | −2210% | – |
| FCF margin | −3010% | – |
| Return on equity | −144% | 113% (better) |
| Return on invested capital | – | −8.4% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.65 | 4.98 (better) |
| Altman Z-score | −24.75 | 1.96 (better) |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 6.1% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 6.1% (better) |
| Ownership | ||
| Held by institutions | 22.9% | 40.3% |
| Held by insiders | 2.3% | 23.9% |
| Insider net buying, 12 months | −$10.0K (better) | −$1.2M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 3.5% | 4.2% |
Go deeper
- MCRB stock overview
- MCRB income statement
- MCRB valuation and score
- ORMP stock overview
- ORMP income statement
- ORMP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.